SAN DIEGO, April 20, 2015 /PRNewswire/ -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim® and t:flex™ Insulin Pumps, today commenced shipments of t:slim Pumps featuring enhanced software. The updated software, based on customer and healthcare provider feedback, includes an expansion of the reverse correction function, the ability to enter a manual bolus directly in the suggested bolus window, off-pump cartridge filling, and other features to enhance convenience and flexibility.
Tandem is actively working on a project to provide current t:slim Pump users the ability to update their pump software remotely, similar to other modern consumer devices. The Company plans to submit a filing for this remote update capability to the U.S. Food and Drug Administration (FDA) later this year.
"Innovation is at the heart of our company, as is listening to our customers," said Kim Blickenstaff, President and CEO of Tandem Diabetes Care. "As we enhance our products, we want to offer the new features to our existing customers as quickly as possible. The ability to remotely update pumps is a way to do this, and we look forward to working with the FDA to bring our customers this benefit."
About the t:slim Insulin Pump
The t:slim Insulin Pump, consistently ranked #1 by pump users in independent patient surveys1, is the first insulin pump with a touch screen approved by the FDA. The streamlined, user-friendly interface provides rapid access to the features people use most, eliminating the need for excessive scrolling and button pressing, and making the t:slim Pump simple to learn and simple to use. It is the slimmest and smallest durable insulin pump on the market, yet still holds up to 300 units of insulin. The t:slim Pump also incorporates a built-in rechargeable battery and micro-USB port for convenient charging and fast data transfer speeds.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures the t:slim® Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the t:flex™ Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim, #tflex and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/TandemDiabetes.
The t:slim® Insulin Delivery System and the t:flex™ Insulin Delivery System are each intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin, for individuals 12 years of age and greater. The t:slim and t:flex Pumps are available for sale by or on the order of a physician.
t:slim and Tandem Diabetes Care are registered trademarks of Tandem Diabetes Care, Inc. t:flex is a trademark of Tandem Diabetes Care, Inc.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to the Company's development project to allow current t:slim Pump users to remotely update their existing pumps with software changes and the Company's current plan to submit this remote software update feature for FDA review during 2015. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including: risks associated with
the development of new products generally, including possible delays in the Company's product development programs; possible future actions of the FDA or any other regulatory body or governmental authority, including the potential that the FDA may not agree with our proposed pathway for regulatory approval; and other risks identified in the Company's most recent Annual Report on Form 10-K, as well as other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.
1 dQ&A USA Diabetes Connections Surveys, 2013-2014.
Logo - http://photos.prnewswire.com/prnh/20131220/LA37333LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tandem-diabetes-care-now-shipping-tslim-insulin-pump-with-updated-software-300068266.html
SOURCE Tandem Diabetes Care, Inc.